Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating acute and chronic pain by local antagonism of CGRP receptors, or combination with sodium channel inhibition or with anti-inflammatory agents

a technology of cgrp receptors and local antagonism, which is applied in the direction of drug compositions, peptides, peptides/protein ingredients, etc., can solve the problems of suspension of clinical trials of small molecules, inability to administer saxitoxin systemically, and inability to achieve the effect of reducing associated neurogenic inflammation and reducing undesirable systemic side effects

Active Publication Date: 2019-05-14
AFASCI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015]Also provided are improved techniques and methods for local delivery to a subject of a therapeutically effective amount of one or more of the pain-relieving compositions as described herein to provide local pain relief and, in various embodiments, to reduce associated neurogenic inflammation in a mammal. In various embodiments, these methods also yield reduced undesirable systemic side effects.

Problems solved by technology

Acute or chronic pain is one of the most widespread and frequent human complaints, as well as one of the most difficult syndromes to treat successfully with drugs or surgery.
Systemic antagonism of CGRP often produced undesirable side effects leading to suspension of clinical trials of small molecule CGRP antagonists (Benemei, et al., 2009; Edvinsson and Warfvinge, 2013).
However their action usually lasts for only a few hours and mainly relieves acute nociceptive pain.
However, because of undesired systemic side effects, saxitoxin cannot be administered systemically.
Although this procedure may provide peripheral therapy for migraine, Botox also paralyzes skeletal muscles, which may lead to unwanted side-effects (except for its currently approved local cosmetic use).
However, none of these treatment options provides acceptable systemic pain relief for more than 50% of the treated patients.
In addition, all of these drugs are known to have undesirable systemic side effects (Uhl, et al., 2014).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating acute and chronic pain by local antagonism of CGRP receptors, or combination with sodium channel inhibition or with anti-inflammatory agents
  • Compositions and methods for treating acute and chronic pain by local antagonism of CGRP receptors, or combination with sodium channel inhibition or with anti-inflammatory agents
  • Compositions and methods for treating acute and chronic pain by local antagonism of CGRP receptors, or combination with sodium channel inhibition or with anti-inflammatory agents

Examples

Experimental program
Comparison scheme
Effect test

example 1

of Peptides

[0208]In the examples below, unless otherwise stated, temperatures are given in degrees Celsius ° C.); operations were carried out at room or ambient temperature (typically a range of from about 18-25° C.; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (typically, 4.5-30 mmHg) with a bath temperature of up to 60° C.; the course of reactions was typically followed by TLC and reaction times are provided for illustration only; melting points are uncorrected. The following conventional abbreviations are also used: mp (melting point), L (liter(s)), mL (milliliters), mmol (millimoles), g (grams), mg (milligrams), min (minutes), LC-MS (liquid chromatography-mass spectrometry) and h (hours), PS (polystyrene), DIE (diisopropylethylamine). 1H Nuclear magnetic resonance (NMR) spectra were in all cases consistent with the proposed structures. Characteristic chemical shifts (δ) are given in parts-per-million downfield from tetramethylsilane usi...

example 2

ssay

[0222]Native Receptor Binding Assay:

[0223]The binding of 125I-CGRP to receptors in SK-N-MC cell membranes is carried out essentially as described (Edvinsson et al. (2001) Eur. J. Pharmacol. 415, 39-44). Briefly, membranes (25 μg) were incubated in 1 mL of binding buffer [10 mM HEPES, pH 7.4, 5 mM MgCl2 and 0.2% bovine serum albumin (BSA)] containing 10 pM. 125I-CGRP and antagonist. After incubation at room temperature for 3 h, the assay is terminated by filtration through GFB glass fiber filter plates (PerkinElmer) blocked with 0.5% polyethyleneimine for 3 h. The filters are washed three times with ice-cold assay buffer (10 mM HEPES, pH 7.4 and 5 mM MgCl2), then the plates are air dried. Scintillation fluid (50 μL) is added and the radioactivity is counted on a Topcount (Packard Instrument). Data analysis is carried out by using Prism and the K, is determined by using the Cheng-Prusoff equation (Cheng & Prusoff (1973) Biochem. Pharmacol. 22, 3099-3108).

[0224]Recombinant Receptor...

example 3

ogical Evaluations

[0232]Embodiment studies were utilized to examine whether peripheral antagonism of CGRP receptors with CGRP 8-37 or an active AFA-peptide could attenuate acute and chronic pain caused by a variety of disorders. Transdermal or cutaneous analgesia produced by CGRP 8-37, an AFA-peptide, or a combination of a therapeutic, including, but not limited to lidocaine, saxitoxin, dexamethasone, ibuprofen, and via a selected delivery method as appropriate for a specific pain model and test, were detailed in specific examples. All studies were performed in male rats (Sprague-Dawley, 200-280 g, Harlan), and each experimental group had n=6-8 rats. All drug solutions were freshly prepared in the vehicle containing 0.5% hydroxyl propyl cellulose and 2% DMSO, unless specified otherwise.

[0233]Embodiments contemplated are therapeutic methods utilizing one or more of the therapeutic composition as described above. On such therapeutic method is a method for treating pain or an inflammat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thermal thresholdaaaaaaaaaa
thickaaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

The present invention provides compositions, and methods for local administration of certain peptides or combination with certain small molecules that produce analgesia and anti-inflammation in a mammal. Exemplary polypeptides provide peripheral analgesia and anti-inflammation when administered via local topical, subcutaneous, intradermal, or intranasal administration, to provide analgesia and anti-inflammation. Through antagonism of peripheral CGRP receptors alone, or in combination with inhibition of sensory sodium channels or anti-inflammation, the compositions of the invention provide local therapeutic pain relief with minimal undesired systemic side effects in a subject. Also provided are improved peptide delivery techniques including microneedle unit dose administering apparatus and methods. Also provided are hydrogel formulations for sustained local delivery to a subject of one or more of the compositions according to the invention in a therapeutically effective amount, thereby providing local pain relief and / or reducing associated inflammation.

Description

STATEMENT OF GOVERNMENT RIGHTS[0001]This invention was made with Government support under Grant 5 R44DA026363-03 awarded by the National Institute on Drug Abuse. The Government has certain rights in this invention.FIELD OF THE INVENTION[0002]The present invention relates to compositions and methods for treating acute and chronic or persistent pain via a local application of a CGRP receptor antagonist peptide or a combination of a CGRP antagonist and a sodium channel blocker or an anti-inflammatory drug to a patient in need of such treatments.BACKGROUND OF THE INVENTION[0003]Acute or chronic pain is one of the most widespread and frequent human complaints, as well as one of the most difficult syndromes to treat successfully with drugs or surgery. Some types of acute or chronic pain are particularly related to neuropathic and / or neurogenic inflammation. Such neurogenic inflammation can be triggered by the activation of unmyelinated sensory neurons through noxious stimuli and the subse...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K38/00A61P23/00A61K38/10A61K38/04C07K5/00C07K7/00C07K16/00C07K17/00C07K14/575A61K9/00A61K45/06A61K38/23C07K7/08C07K14/72
CPCC07K14/57527A61K9/0021A61K38/10A61K45/06C07K7/08C07K14/723A61K38/23A61K38/00A61P23/00
Inventor XIE, XINMINPASCUAL, CONRADOXIE, XIXIE, JAMES
Owner AFASCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com